Sign inJoin waitlistJoin the waitlist

Matthew Matasar

Chief, Division of Blood Disorders, Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center · Rutgers Health

Credentials: · · · · ·

History

Division of Blood Disorders · Rutgers Health
Present
Rutgers Health
Present

Medical Oncology
2003–2005
Internal Medicine
2000–2003
Mailman School of Public Health
Harvard Medical School
1996–2000
Harvard College
1992–1996

Research

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
New England Journal of Medicine · 2022 · 793 citations
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology · 2020 · Last of 16 authors · 647 citations
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
The Lancet Oncology · 2022 · 398 citations

AZ
Andrew Zelenetz
51 papers
AN
Ariela Noy
43 papers
PH
Paul Hamlin
43 papers
SH
Steven Horwitz
42 papers
AK
Anita Kumar
41 papers
Craig Moskowitz
40 papers
AM
Alison Moskowitz
38 papers
DS
David Straus
37 papers
Lia Palomba
32 papers
AY
Anas Younes
26 papers
GS
Gilles Salles
22 papers
Joachim Yahalom
21 papers

Clinical trials

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2007–2013
SynKIR-310 for Relapsed/Refractory B-NHL
Site PI · Recruiting · Phase 1
Verismo Therapeutics
2024–2028
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 1, Phase 2
Cellectis S.A.
2022–2027